Cue Biopharma Inc (CUE)
1.02
-0.01
(-0.97%)
USD |
NASDAQ |
Nov 22, 16:00
1.05
+0.03
(+2.94%)
After-Hours: 20:00
Cue Biopharma Free Cash Flow: -38.32M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
September 30, 2024 | -38.32M |
June 30, 2024 | -38.60M |
March 31, 2024 | -38.97M |
December 31, 2023 | -39.96M |
September 30, 2023 | -39.52M |
June 30, 2023 | -38.67M |
March 31, 2023 | -41.21M |
December 31, 2022 | -41.98M |
September 30, 2022 | -42.11M |
June 30, 2022 | -41.80M |
March 31, 2022 | -38.91M |
December 31, 2021 | -39.75M |
September 30, 2021 | -36.21M |
June 30, 2021 | -37.61M |
Date | Value |
---|---|
March 31, 2021 | -34.59M |
December 31, 2020 | -33.09M |
September 30, 2020 | -32.43M |
June 30, 2020 | -33.62M |
March 31, 2020 | -33.29M |
December 31, 2019 | -30.84M |
September 30, 2019 | -28.41M |
June 30, 2019 | -25.79M |
March 31, 2019 | -26.33M |
December 31, 2018 | -28.27M |
September 30, 2018 | -26.11M |
June 30, 2018 | -23.40M |
March 31, 2018 | -19.76M |
December 31, 2017 | -13.35M |
Free Cash Flow Range, Past 5 Years
-42.11M
Minimum
Sep 2022
-30.84M
Maximum
Dec 2019
-37.57M
Average
-38.63M
Median
Free Cash Flow Benchmarks
Biomarin Pharmaceutical Inc | 300.88M |
Arbutus Biopharma Corp | -71.92M |
GlycoMimetics Inc | -35.02M |
FibroGen Inc | -126.23M |
Cidara Therapeutics Inc | -160.15M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -7.527M |
Cash from Investing (Quarterly) | 0.098M |
Cash from Financing (Quarterly) | 9.821M |
Free Cash Flow Per Share (Quarterly) | -0.1469 |
Free Cash Flow to Equity (Quarterly) | -6.568M |
Free Cash Flow Yield | -75.88% |